Join on Telegram
Health

American Cancer Society recommends biennial PSA testing for average‑risk men aged 50‑69

The American Cancer Society has reversed its 2010 stance, urging men 50 to 69 with average risk to undergo prostate‑specific antigen screening every two years, while high‑risk groups are advised to start annual testing at age 45.

By LAS News Desk · Published 13 Nov 2026, 06:44 WAT

American Cancer Society recommends biennial PSA testing for average‑risk men aged 50‑69
Photo: U.S. Army photo by Sgt. Austin Robertson / Wikimedia Commons, Public domain. Illustrative photo; not taken at this event.

The American Cancer Society (ACS) released a major update to its prostate‑cancer screening guidelines on Thursday, recommending routine prostate‑specific antigen (PSA) testing for men aged 50 to 69 who are at average risk. The new guidance calls for a PSA test every two years for this group, a clear departure from the 2010 recommendations that left screening to shared decision‑making between patients and physicians.

High‑risk men – defined as Black men and non‑Black men with a strong family history of prostate cancer – are now advised to begin annual PSA testing at age 45. For Black men, yearly screening starts at 45 regardless of family history, reflecting their higher incidence and mortality rates. Non‑Black men with a close relative diagnosed before age 65, or with multiple affected relatives, also face yearly testing from 45. Men with a single relative diagnosed at age 65 or older are recommended to start at 45 but may be screened biennially.

Men aged 70 to 74 are instructed to discuss continued screening with their doctors, while those 75 and older are generally not recommended for routine PSA testing.

Background

The ACS’s previous prostate‑cancer screening guidance, issued in 2010, made no universal recommendation for routine PSA testing. Instead, it suggested that men at age 50 engage in shared decision‑making with their healthcare providers to determine whether screening was appropriate. Over the past decade, concerns about PSA test specificity – leading to unnecessary biopsies and overtreatment – caused many professional bodies to scale back routine screening recommendations.

Recent studies, however, have shown that PSA‑based screening can reduce disease‑specific mortality in certain populations. The ACS guideline authors cited these findings as the basis for reinstating routine screening for average‑risk men and strengthening recommendations for high‑risk groups. The updated guidance also emphasizes the goal of lowering advanced‑stage diagnoses among Black men, who are disproportionately affected by prostate‑cancer mortality.

Why it matters

Prostate cancer remains one of the most common cancers among men in the United States. The ACS’s revised recommendations aim to improve early detection, particularly for groups with higher risk. By encouraging biennial testing for average‑risk men, the society hopes to catch cancers at a stage when treatment is more effective, potentially reducing mortality.

For Black men, the annual screening starting at age 45 is intended to address the documented disparity in outcomes. The guideline authors explicitly noted that increased surveillance could lower the number of Black patients presenting with advanced disease.

Healthcare providers will need to incorporate these new age‑specific intervals into routine practice, and insurers may adjust coverage policies to align with the ACS recommendations. Patients will also be faced with clearer guidance on when to initiate and how frequently to undergo PSA testing, reducing uncertainty that previously surrounded shared‑decision‑making.

What happens next

The ACS has not indicated any immediate further revisions, but the guidance notes that screening decisions for men aged 70 to 74 should be individualized, and that routine testing should cease after age 80 or in men with a life expectancy of less than ten years. Clinicians are expected to discuss the benefits and harms of continued screening with patients in these older age brackets.

The updated recommendations were released on Thursday and are now part of the ACS’s official guidance documents. No additional policy changes or legislative actions were reported in the source material, though the STAT article referenced ongoing attention to health‑policy discussions in the Senate health committee.

Overall, the ACS’s shift signals a renewed confidence in PSA testing as a tool for early prostate‑cancer detection, aligning current practice with emerging evidence and public‑health goals.

Sources

Spotted an error? · Corrections policy

#prostate cancer#screening#american cancer society#psa test#health policy

Related stories

NHS England faces 10,000 patient shortfall in cancer treatment target
Health

NHS England faces 10,000 patient shortfall in cancer treatment target

NHS England is projected to miss its 2027 cancer treatment target by nearly 10,000 patients, with experts citing insufficient staff and equipment as primary causes.

Photo: Harvy334 / Wikimedia Commons · CC0

LAS News Desk · 15 Nov 2026, 11:19 WAT · 1 source

Wales plans ban on energy drinks for under-16s following England's move
Health

Wales plans ban on energy drinks for under-16s following England's move

The Welsh government is considering prohibiting the sale of high-caffeine energy drinks to under-16s, a move supported by young people and experts but opposed by the soft drinks industry.

LAS News Desk · 7 Nov 2026, 08:10 WAT · 2 sources

Steve Smith ruled out of Cape Town Test after neck injury
Sport

Steve Smith ruled out of Cape Town Test after neck injury

Australia’s captain Steve Smith was ruled out of the deciding third Test against South Africa in Cape Town after a late fitness test failed, forcing the team to name a replacement.

Photo: NAPARAZZI / Wikimedia Commons · CC BY-SA 2.0

LAS News Desk · 27 Oct 2026, 09:46 WAT · 5 sources

FDA shelves Trump‑era fast‑track drug review programme
Health

FDA shelves Trump‑era fast‑track drug review programme

The FDA has quietly dropped the National Priority Voucher program launched in June 2025, after no new vouchers were issued since former Commissioner Marty Makary left in May. The move follows criticism of the programme’s political oversight and lack of progress.

LAS News Desk · 12 Nov 2026, 20:16 WAT · 2 sources

Senate health panel blocks Trump‑nominated Jim O’Neill from leading the National Science Foundation
Health

Senate health panel blocks Trump‑nominated Jim O’Neill from leading the National Science Foundation

Republican Senator Bill Cassidy halted the confirmation of Jim O’Neill as NSF director, citing a failure to defend scientific integrity during his tenure at HHS and the CDC, ending the Trump administration’s pick for the agency.

LAS News Desk · 19 Nov 2026, 09:46 WAT · 7 sources

Women with cancer report treatment‑induced menopause and call for better support
Health

Women with cancer report treatment‑induced menopause and call for better support

Breast‑cancer survivors in the UK say chemotherapy and surgery have triggered early menopause, prompting calls for clearer information and services, as the Department of Health pledges to include menopause in cancer‑care plans.

LAS News Desk · 8 Nov 2026, 19:17 WAT · 1 source

More Health news ›

Get the LAS News briefing

The day's top stories from Nigeria, Africa and the world, in your inbox.